|
KMID : 1039120230120040319
|
|
Clinical and Experimental Vaccine Research
2023 Volume.12 No. 4 p.319 ~ p.327
|
|
|
Serological response 5 months after the BNT162b2 COVID-19 vaccination in patients with various hematological disorders in Japan
|
|
Yoshiaki Marumo
Takashi Yoshida
Yuki Furukawa
Kenji Ina
Ayumi Kamiya
Takae Kataoka
Satoshi Kayukawa
|
|
|
Abstract
|
|
|
Purpose : Patients with hematological malignancies are at an increased risk of severe infection with coronavirus disease 2019 (COVID-19). However, developing an adequate immune response after vaccination is difficult, especially in patients with lymphoid neoplasms. Since the long-term effects of the BNT162b2 vaccine are unclear, the humoral immune response 5 months after the two vaccinations in patients with hematological disorders was analyzed.
Materials and Methods : Samples were collected from 96 patients vaccinated twice with BNT162b2 and treated with at least one line of an antitumor or immunosuppressive drug in our hospital from November 2021 to February 2022. Serum anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) spike (S) antibody titers were analyzed. Patients were age- and sex-matched using propensity matching and compared with a healthy control group. Patients with serum anti-SARS-CoV-2 S antibodies were defined as ‘responder’ if >50 U/mL. The patients had B-cell non-Hodgkin lymphoma (B-NHL), multiple myeloma, chronic myeloid leukemia, etc.
Results : Patients had significantly low antibody levels (median, 55.3 U/mL vs. 809.8 U/mL; p<0.001) and a significantly low response rate (p<0.001). Multivariate analysis showed that patients with B-NHL, aged >72 years, were associated with a low response to vaccination. There were no significant differences between patients with chronic myeloid leukemia and healthy controls.
Conclusion : Our study shows that patients with hematological disorders are at risk of developing severe COVID-19 infections because of low responsiveness to vaccination. Moreover, the rate of antibody positivity differed between the disease groups. Further studies are warranted to determine an appropriate preventive method for these patients, especially those with B-NHL.
|
|
|
KEYWORD
|
|
|
BNT162 vaccine, COVID-19, Hematologic diseases, B-cell lymphoma, Chronic myeloid leukemia
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|